Bankole A. Johnson
Neuroscience · Indiana University
Publications
1,158
Citations
12,287
Est. group size
—
Recurring co-author estimate
Active years
58
Publishing since 1968
Bankole A. Johnson studies medical treatments for addiction, with a particular focus on alcohol use disorder and, to a lesser extent, cocaine use disorder. Much of the work involves clinical trials testing whether existing or novel medications (such as low-dose ondansetron, a drug that blocks certain serotonin receptors) can reduce heavy drinking, often using genetic and biological markers to match treatments to patients (an approach called precision medicine). The research also addresses how to best measure treatment success and includes statistical methodology for analyzing trial data.
Publication activity has been steady over the last decade, averaging around two papers per year with a modest peak in 2023.
Generated by claude-opus-4-8 from public bibliographic data · Jul 9, 2026
Typically publishes in teams of ~7 · 18% small-team papers (≤3 authors) · across 12 venues
- POS0781 EFFICACY AND SAFETY OF ORAL DEUCRAVACITINIB IN PATIENTS WITH CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS: RESULTS FROM PAISLEY CLE, A GLOBAL, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL
Annals of the Rheumatic Diseases · 2025
- Safety and compliance of long-term low-dose ondansetron in alcohol use disorder treatment.
European Journal of Internal Medicine · 2024
- Low-dose ondansetron: A candidate prospective precision medicine to treat alcohol use disorder endophenotypes
European Journal of Internal Medicine · 2024
- A critical scientific evaluation of a purportedly negative data report – response to Seneviratne et al. 2022
Frontiers in Psychiatry · 2023
- A Prospective Precision Medicine Phase 3 Clinical Trial of Low-dose Ondansetron (a 5-ht3 Antagonist) to Treat Heavy and Very Heavy Drinkers With Alcohol Use Disorder
Research Square · 2023
- A Phase 3 Randomized Precision Medicine Clinical Trial Using Low-Dose Ondansetron (a 5-HT3 Antagonist) to Treat Alcohol Use Disorder
Research Square · 2023
- Validation of serotonin transporter mRNA as a quantitative biomarker of heavy drinking and its comparison to ethyl glucuronide/ethyl sulfate: A randomized, double‐blind, crossover trial
Alcoholism Clinical and Experimental Research · 2022
- The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance
Science · 2022
- A Prospective Pharmacogenetic Phase 3 Clinical Trial of Low-Dose Ondansetron (A 5-HT3 Antagonist) to Treat Heavy and Very Heavy Drinkers With Alcohol Use Disorder
Research Square · 2022
- A randomized, double-blind, placebo-controlled trial of ondansetron for the treatment of cocaine use disorder with post hoc pharmacogenetic analysis
Drug and Alcohol Dependence · 2021
- Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials
JAMA Psychiatry · 2019
- Statistical Analysis of Zero-Inflated Nonnegative Continuous Data: A Review
Statistical Science · 2019
- Addiction Medicine: Science and Practice
DIAL (Catholic University of Leuven) · 2019
- Variable selection for random effects two-part models
Statistical Methods in Medical Research · 2018
- Toward Rational, Evidence‐Based, and Clinically Relevant Measures to Determine Improvement Following Treatment for Alcohol Use Disorder
Alcoholism Clinical and Experimental Research · 2017
- Alcoholism Clinical and Experimental Research×3
- Research Square×3
- Physical Review Letters×2
- European Journal of Internal Medicine×2
- Science×1
- Sean O’Connor
Neuroscience · Indiana University
- Ann Kosobud
Neuroscience · Indiana University
- Jessica Weafer
Neuroscience · The Ohio State University
- Michael P. Smoker
Neuroscience · Indiana University
- Brandon G. Oberlin
Neuroscience · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Sep 1, 2026.
Claim or correct this profile